In a 12-month trial evaluating the effects of pentoxifylline on inflammatory parameters in patients with CKD (mean eGFR 40.1 or 42.3 mL/min/1.73 m2 for placebo or pentoxifylline group, respectively; median 24 h urine albumin 115 or 56 mg for placebo or pentoxifylline group, respectively), the participants received a placebo or 400 mg of pentoxifylline twice daily. Here, ALB is linked to chronic kidney disease.